Form 4: Gain Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Khalid Islam acquired 15,000 stock options in Gain Therapeutics, Inc. on June 24, 2024.
Summary
- On June 24, 2024, Khalid Islam, a director of Gain Therapeutics, Inc. (GANX), acquired 15,000 stock options.
- The exercise price of these options is $1.29.
- The options vest in 12 equal monthly installments starting July 24, 2024, contingent upon continuous service.
- The options expire on June 24, 2034.
- Following the transaction, Khalid Islam directly owns 15,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/24/2024 | Date of transaction: Khalid Islam acquired 15,000 stock options. |
| 07/24/2024 | Vesting start date: Options vest in 12 equal monthly installments commencing on this date. |
| 06/24/2034 | Expiration date: Options expire on this date. |
| 06/26/2024 | Date of report: Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.